Pacific EdgeASX:PEB -4.00%42 Quick Ratio is 1.72 as of Mar. 2026, which is 78% below its 10-year median of 7.92. GuruFocus rates ASX:PEB with a GF Score™ of 42/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Pacific Edge ranks better than 50.7% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Pacific Edge's quick ratio for the quarter that ended in Mar. 2026 was 1.72.
Pacific Edge has a quick ratio of 1.72. It generally indicates good short-term financial strength.
The historical rank and industry rank for Pacific Edge's Quick Ratio or its related term are showing as below:
ASX:PEB'
s Quick Ratio Range Over the Past 10 Years
Min: 1.72 Med: 7.92 Max: 18.27
Current: 1.72
During the past 13 years, Pacific Edge's highest Quick Ratio was 18.27. The lowest was 1.72. And the median was 7.92.
ASX:PEB's Quick Ratio is ranked better than 50.7% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.67
vs ASX:PEB: 1.72
Pacific Edge (ASX:PEB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Pacific Edge Quick Ratio Related Terms
Pacific Edge Quick Ratio Historical Data
* Premium members only.
The historical data trend for Pacific Edge's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Pacific Edge's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Edge Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Pacific Edge's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Pacific Edge's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Edge (ASX:PEB) has a Quick Ratio of 1.72 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Pacific Edge and its competitors. This is 78% below median its historical median of 7.92. Over the past decade, Pacific Edge's Quick Ratio has ranged from 1.72 to 18.27. According to the industry distribution chart, Pacific Edge ranks #106 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 49.3%.
Is Pacific Edge's Quick Ratio too high?
Pacific Edge's current Quick Ratio of 1.72 is 78% below median its 10-year median of 7.92. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 18.27. The Medical Diagnostics & Research industry median Quick Ratio is 1.67. Pacific Edge's value of 1.72 is 3% above this industry median. Based on the distribution chart, Pacific Edge ranks #106 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Pacific Edge has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #106 out of 215 companies for Quick Ratio. This puts Pacific Edge in the upper half of its industry. The industry median Quick Ratio is 1.67. Pacific Edge's value of 1.72 is 3% above this benchmark. Historically, Pacific Edge's own Quick Ratio has ranged from 1.72 to 18.27 over the past decade. While the company's 10-year median is 7.92 vs. the industry median of 1.67, Pacific Edge has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.67, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Edge's current Quick Ratio of 1.72 is 3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Pacific Edge and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Edge's current Quick Ratio is 1.72, which is 78% below median its own 10-year median of 7.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.24 — trading 380% above its estimated fair value. The current Quick Ratio is 1.72, which is 78% below median its 10-year median of 7.92 and 3% above the Medical Diagnostics & Research industry median of 1.67. Pacific Edge's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Quick Ratio is 1.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Edge (ASX:PEB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued.
The current stock price of A$0.24 is trading 380% above its estimated GF Value™ of A$0.05.
GuruFocus considers Pacific Edge to be Significantly Overvalued.
Key valuation signals for ASX:PEB:
Quick Ratio: 1.72 (78% below median its 10-year median of 7.92)
GF Value™: A$0.05 vs. price of A$0.24 (380% above fair value)
Industry Position: 3% above the Medical Diagnostics & Research median (#106 of 215)
No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score
Get the complete analysis for ASX:PEB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PEB has been successfully added to your 
